The Methodist Hospital Research Institute
Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are undergoing evaluation for or waitlisted for liver transplantation will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolization (TACE) or transarterial radioembolization (TARE). We hypothesize that atezolizumab and bevacizumab can appropriately bridge patients with HCC beyond MC to transplantation and not increase the risk of 1-year post-transplant rejection.
Hepatocellular carcinoma (HCC) represents the second most common cause of cancer-related death and accounts for over 80% of primary liver cancers worldwide. Curative treatment options include surgical resection in patients with well compensated liver function and radio frequency ablation in small tumors. However, in 90% of patients, HCC occurs in the setting of cirrhosis where optimal management remains liver transplantation (LT) with 5-year survival rates of approximately 80%. Despite the success of LT in treating HCC, only a small portion of patients fit into standard Milan Criteria to recei…
Inclusion Criteria: 1. Male or female, aged ≥18 years old at the time of signing Informed Consent Form 2. Measurable or evaluable disease per RECIST v1.1 or mRECIST of unresectable HCC outside of Milan criteria 3. Histologically or radiologically proven HCC, without extrahepatic disease. Patients who consent to a fresh tissue biospy, and under the discretion of the Investigators, will provide a baseline biopsy sample for diagnosis and correlative studies. Archival tumor tissue may be used to confirm HCC in patients who do not consent to a fresh tissue biopsy. 4. Prior remote LRT is allowed if…
1200 mg administered every three weeks for up to 6 months (up to 8 cycles) during the liver transplant waiting period
15 mg/kg administered every three weeks for up to 6 months (up to 8 cycles) during the liver transplant waiting period
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.